Table 3.
Antibody response to COVID-19 vaccination in age- and sex-matched healthy volunteers and patients with CLD 2 weeks after the second SARS-CoV-2 vaccine dose (T2).
| Antibody titre in healthy volunteers | ChAdOx1 nCoV-19 (n = 9) | mRNA-1273 (n = 6) | BNT162b2 (n = 68) | Total (N = 83) | p value |
|---|---|---|---|---|---|
| IgG Wuhan-Hu-1 (nM) | 113.4 (54.1–349.5) | 709.6 (545.2–851.5) | 409.6 (244.2–535.1) | 409.2 (237.1–557.5) | <0.001 |
| IgG B.1.617 (nM) | 77.9 (35.8–285.0) | 408.3 (223.1–485.9) | 269.4 (137.8–375.2) | 269.8 (135.6–381.2) | n.s. |
| IgG B.1.1.529 (nM) | 89.3 (20.4–194.6) | 298.5 (107.3–473.3) | 125.5 (80.1–213.9) | 126.1 (78.8–219.8) | n.s. |
| IgM (nM) | 0.4 (0.2–1.6) | 11.3 (3.5–17.6) | 0.9 (0.3–1.9) | 0.9 (0.3–2.1) | <0.01 |
| % neutralisation |
39.3 (31.6–50.4) |
83.5 (63.2–91.9) |
58.7 (46.7–74.2) |
57.0 (45.1–74.2) |
<0.001 |
|
Antibody titre in patients with CLD |
ChAdOx1 nCoV-19 (n = 6) |
mRNA-1273 (n = 16) |
BNT162b2 (n = 61) |
Total (N = 83) |
pvalue |
| IgG Wuhan-Hu-1 (nM) | 31.9 (17.7–56.7)∗ | 496.2 (312.0–1,104.310) | 534.0 (299.2–707.1)∗ | 494.2 (231.4–713.0) | <0.01 |
| IgG B.1.617 (nM) | 20.9 (3.9–43.7)∗ | 352.8 (195.7–785.7) | 300.2 (179.2–507.2) | 296.0 (136.1–524.0) | <0.01 |
| IgG B.1.1.529 (nM) | 3.9 (1.2–6.7)† | 158.6 (85.1–358.8) | 143.0 (67.0–231.6) | 132.3 (56.3–238.3) | <0.001 |
| IgM (nM) | 0.7 (0.5–2.2) | 3.7 (1.6–8.5) | 1.5 (0.9–3.1)† | 1.6 (0.9–3.7) | <0.01 |
| % neutralisation | 47.3 (41.3–67.3) | 50.8 (27.5–94.8) | 65.6 (50.7–81.6) | 63.1 (43.7–81.5) | n.s. |
Data are displayed as median (IQR). The Kruskal–Wallis test was used to compare the variables between the three vaccine developers, and the Mann–Whitney test to compare between healthy volunteers and patients with CLD. A value of p <0.05 was considered statistically significant. CLD, chronic liver disease.
∗p <0.05.
†p <0.01 comparing with healthy volunteers.